Lake Street analyst Thomas Flaten downgraded OncoCyte to Hold from Buy with a price target of 50c, down from $3, after the company announced the departure of Ronnie Andrews as CEO. The CEO’s exit marks "the end of an eventful period in the company’s history" and his lower rating reflects the incremental near-term uncertainty created by this change, Flaten tells investors.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on OCX:
- Oncocyte Announces the Appointment of Louis E. Silverman as a Member of Its Board of Directors
- Oncocyte Announces Executive Leadership Changes
- OncoCyte CEO Ronnie Andrews to step down, Joshua Riggs named interim CEO
- OncoCyte price target lowered to $1 from $1.50 at Piper Sandler
- Oncocyte Reports Third Quarter 2022 Financial Results
